SACRAMENTO, CA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)CALIFORNIA BIOTECHNOLOGY FOUNDATION, founded in 2008, is a small nonprofit in the Science & Technology sector that reported $773K in total revenue in fiscal year 2023. Revenue decreased 11% compared to the prior year.
THE PRIMARY OBJECTIVES AND PURPOSES OF THIS CORPORATION SHALL BE TO EDUCATE THE PUBLIC CONCERNING BIOTECHNOLOGY AND HEALTHCARE-RELATED FIELDS
HIGHLIGHT LIFE SCIENCE INDUSTRYS EFFORTS ON COMBATING COVID-19 AND OTHER ILLNESSES*CBF CONTINUED PUBLISHING WEEKLY COVID-19 UPDATE NEWSLETTER IN 2022 WITH EMERGING NEWS AND PERTINENT INFORMATION...
HIGHLIGHT LIFE SCIENCE INDUSTRYS EFFORTS ON COMBATING COVID-19 AND OTHER ILLNESSES*CBF CONTINUED PUBLISHING WEEKLY COVID-19 UPDATE NEWSLETTER IN 2022 WITH EMERGING NEWS AND PERTINENT INFORMATION RELATED TO LIFE SCIENCE ADVANCEMENTS IN TESTING, TREATMENTS, AND VACCINES.*CBF USED SOCIAL MEDIA, THE WEBSITE, AND DIGITAL ADVERTISING TO SHARE UPDATES ON THE EMERGING MPOX PUBLIC HEALTH CHALLENGE. MATERIALS INCLUDED HIGHLIGHTS OF EFFORTS TO PREVENT MPOX FROM REACHING PANDEMIC STATUS. THESE EFFORTS WERE HIGHLIGHTED IN CBFS MONTHLY NEWSLETTER.*DEVELOPED COVID-19 TIMELINE FACT SHEET ON VACCINES, TESTS, TREATMENTS FOR MONTHLY NEWSLETTER.OTHER EDUCATION *OVERVIEW OF LIFE SCIENCES IN CALIFORNIA TO POLICYMAKERS AT A BRIEFING.*ENGAGED POLICYMAKERS THROUGH REGULAR EMAIL UPDATES, NEWSLETTER CONTENT AND SOCIAL MEDIA. *POSITION CBF AS THE GO-TO INFORMATIONAL RESOURCE TO LEARN MORE ABOUT CA LIFE SCIENCES *EVENT TOUR OF WA LIFE SCIENCES WITH INDUSTRY REPRESENTATIVESCOLLATERAL: FACTS SHEETS, UPDATES, AND NEWSLETTERS*COVID-19 TIMELINE OF LIFE SCIENCE MEDICAL INNOVATIONS FACT SHEET: STEPS TAKEN TO COMBAT THE COVID-19 PANDEMIC AND DISPEL MISINFORMATION RELATED TO VACCINE DEVELOPMENT AND DEPLOYMENT.*LIFE SCIENCE INNOVATIONS FIGHT COVID-19 FACT SHEET: CAS ROLE IN DEVELOPING APPROACHES TO TESTING, CLINICAL TRIALS, VACCINES, AND TREATMENTS.*JAMA STUDY EXAMINES WHETHER 340B DRUG DISCOUNT PROGRAM GENUINELY SERVES VULNERABLE COMMUNITIES FACT SHEET: DEVELOPED IN RESPONSE TO A JAMA STUDY SHOWING THAT 340B BENEFITS PRIMARILY SERVED WHITE, AFFLUENT AREAS.*DMHC REPORT SHOWS HEALTH PLAN PROFIT AND NON-MEDICAL EXPENSES FAR EXCEED RX EXPENDITURES FACT SHEET: DMHC REPORTS ON PRESCRIPTION DRUG CONSUMER EXPENDITURES. MAINTAIN STAKEHOLDER RELATIONSHIPS*BIOCOM 2021 ECONOMIC IMPACT REPORT DATABOOK INFORMATION*REGULARLY ATTENDANCE AT A VARIETY OF STAKEHOLDER MEETINGS*HIGHLIGHT STAKEHOLDERS AT EVENTS, AND IN NEWSLETTERS AND SOCIAL MEDIA *AMPLIFY THE LATEST STAKEHOLDER NEWS AND EVENTS EXECUTE SOCIAL MEDIA CAMPAIGN TO LEVERAGE FACTS AROUND LIFE SCIENCES IN CA*DESIGNED AND EXECUTED MULTIPLE SOCIAL MEDIA AND DIGITAL DISPLAY CAMPAIGNS TO EDUCATE STAKEHOLDERS.*STRATEGICALLY DEPLOYED DIGITAL TO SUPPORT PRIORITY ACTIVITIES OF THE TEAM TO BRING HISTORICALLY OFFLINE ACTIVITIES INTO A DIGITAL ENVIRONMENT. *CBF MAINTAINS A ROBUST ORGANIC SOCIAL MEDIA PRESENCE INCLUDING SHARING THE LATEST NEWS AND EVENTS FROM STAKEHOLDER AND HIGHLIGHTING HEALTHCARE STAKEHOLDERS ON SOCIAL MEDIA DURING AWARENESS MONTHS SUCH AS HISPANIC HERITAGE MONTH AND BREAST CANCER AWARENESS MONTH.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $773,002 | $872,550 | -0.1% |
| Expenses | $765,262 | $899,739 | -0.1% |
| Net Income | $7,740 | $-27,189 | -1.3% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| PATRICIA COOPER | TREASURER | 40.00 |
Officer
Director
|
$122,632 | $35,521 | $158,153 |
| AMANDA BANKS | SECRETARY | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| JOSEPH PANETTA | CHAIRMAN | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $773,002 | $765,262 | $48,401 | $7,740 |
| 2022 | $872,550 | $899,739 | $40,661 | $-27,189 |
| 2021 | $860,600 | $752,305 | $67,850 | $108,295 |
| 2020 | $641,807 | $620,142 | No data | $21,665 |
| 2019 | $607,265 | $642,028 | No data | $-34,763 |
| 2018 | $579,500 | $622,477 | No data | $-42,977 |
Compare CALIFORNIA BIOTECHNOLOGY FOUNDATION with other nonprofits in California and across the country.